Form 4: MEI Pharma Director James P. Flynn Acquires Shares
SEC Form 4
Director James P. Flynn of MEI Pharma, Inc. reports purchasing 7,900 shares of common stock at a weighted-average price of $3.1621 on May 16, 2024.
Summary
- On May 16, 2024, James P. Flynn, a director of MEI Pharma, Inc., acquired 7,900 shares of the company's common stock.
- The shares were purchased at a weighted-average price of $3.1621 per share, with individual prices ranging from $3.11 to $3.21.
- Following the transaction, Mr. Flynn directly owns 7,900 shares of MEI Pharma, Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but it's a relatively small transaction.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider trading activity is closely monitored by regulators and investors as it can provide insights into a company's performance and future prospects. Purchases by insiders are often seen as a positive sign.
Stakeholder Impact
- The purchase could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/16/2024 | Date of transaction: James P. Flynn acquired 7,900 shares of MEI Pharma, Inc. common stock. |
| 05/20/2024 | Date of signature: Form 4 signed by David M. Urso, as attorney in fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.